A clinical trial to study Intracameral Amphotericin B with topical antifungal drugs and topical antifungals alone in management of Deep Fungal Keratitis

Evaluation of Intracameral Amphotericin B in the Management of Deep Fungal Keratitis: Randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/091/000107

Enrollment

Registered

2011-02-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Intracameral amphotericin drugs: topical natamycin 5% hourly during day and two-hourly during night, topical Amphotericin B 0.15% 2-hourly along with 5 micrograms intracmeral amphoteri

Eligibility

Inclusion criteria

Inclusion criteria: Smear- positive deep fungal keratitis with hypopyon whho did not respond to topical natamycin 5 %and amphotericin B 0.15 %

Exclusion criteria

Exclusion criteria: One-eyed patients, children < 12 years of age, and cases with keratitis limited to anterior 1/3rd of stroma and with concurrent sclera involvement

Design outcomes

Primary

Measure	Time frame
Time to Epithelialization and time to resolution of ulcerTimepoint: day1, day3, day7, day 10,day 14, month1 , month 3	—

Secondary

Measure	Time frame
best corrected visual acuityTimepoint: day1, day3, day7, day 10,day 14, month1 , month 3	—

Countries

India

Contacts

Public ContactPreeti Sankaran

R P Centre AIIMS

dr.preeti.sankaran@gmail.com+919810856988

Outcome results